Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Non-Current Assets of $43.5 million for Q1 2026, down 11.97% year-over-year from $49.4 million in Q1 2025, and down 3.27% quarter-over-quarter from $44.9 million in Q4 2025.
Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2026) Analysis & Trends
Tango Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $43.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 11.97% year-over-year to $43.5 million; the TTM figure through Mar 2026 stood at $182.5 million (down 10.59% YoY), while the FY2025 annual figure was $44.9 million, down 10.4% from the prior year.
- Non-Current Assets for Q1 2026 stood at $43.5 million, down from $44.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $62.5 million in Q3 2022, with the low at $10.9 million in Q1 2022.
- The 5-year median for Non-Current Assets is $51.6 million (2024), against an average of $48.3 million.
- Peak annual rise in Non-Current Assets reached 682.88% in 2022, while the deepest fall reached 93.48% in 2022.
- Tango Therapeutics' Non-Current Assets stood at $61.2 million in 2022, then slipped by 8.45% to $56.0 million in 2023, then fell by 10.49% to $50.1 million in 2024, then slipped by 10.4% to $44.9 million in 2025, then retreated by 3.27% to $43.5 million in 2026.
- Business Quant data shows TNGX's Non-Current Assets at $43.5 million in Q1 2026, $44.9 million in Q4 2025, and $46.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 42.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.21 Mn |
| Mar 31, 2026 | 43.47 Mn |
| Dec 31, 2025 | 44.93 Mn |
| Sep 30, 2025 | 46.36 Mn |
| Jun 30, 2025 | 47.79 Mn |
| Mar 31, 2025 | 49.38 Mn |
| Dec 31, 2024 | 50.15 Mn |
| Sep 30, 2024 | 51.60 Mn |
| Jun 30, 2024 | 53.04 Mn |
| Mar 31, 2024 | 54.19 Mn |
| Dec 31, 2023 | 56.03 Mn |
| Sep 30, 2023 | 57.30 Mn |
| Jun 30, 2023 | 58.79 Mn |
| Mar 31, 2023 | 60.77 Mn |
| Dec 31, 2022 | 61.20 Mn |
| Sep 30, 2022 | 62.48 Mn |
| Jun 30, 2022 | 12.31 Mn |
| Mar 31, 2022 | 10.87 Mn |
| Dec 31, 2021 | 7.82 Mn |
| Sep 30, 2021 | 13.80 Mn |